(Total Views: 1520)
Posted On: 05/23/2017 10:14:05 AM
Post# of 1460
For any others like me who are watching the patent information closely, I want to draw your attention to slide 11 "ANAVEX 2-73 also shows synergistic activity with three generations of epilepsy drugs currently on the
market: ETS (Zarontin®), VPA (Depakene®) and Gabapentin (Neurontin®)"
If AVXL is going to pursue a combo patent here, they could follow a similar process as with the Plus patent. By demonstrating SYNERGY, the FDA should allow them to patent the combinations.
PS - FU Scottsmith
market: ETS (Zarontin®), VPA (Depakene®) and Gabapentin (Neurontin®)"
If AVXL is going to pursue a combo patent here, they could follow a similar process as with the Plus patent. By demonstrating SYNERGY, the FDA should allow them to patent the combinations.
PS - FU Scottsmith
(0)
(0)
